Enzyme Inhibitors Market

Enzyme Inhibitors Market: Segmentation

The majority of drugs to treat a number of chronic and life-threatening diseases are developed with a mechanism of action directed towards enzyme inhibition. Enzyme specificity and potency are the important factors considered while developing a drug. A high specificity and potency ensure that a drug will have fewer side effects and a strong therapeutic effect. Enzyme inhibitors are used as diagnostic agents to screen various diseases thus propelling the growth of enzyme inhibitor market.

Enzyme Inhibitors Market: Overview

The emerging therapeutic market for enzyme inhibitors used in human therapeutics is very high. New information is available on biochemistry for enzyme inhibitors and classes of enzyme-inhibiting products with broad current or potential therapeutic applications in large markets. However, more than 90 enzyme inhibitors are currently marketed and double those are under development. A better understanding of the emerging enzyme inhibitors on enzyme mechanism is key. In recent years, use of chemical immobilization has extended to immobilized antibodies or antigens in bio-affinity chromatography. In coming years, it is speculated that immobilization techniques of proteins and enzymes will have a greater impact on point-of-care medical and health business in the enzyme inhibitor market.

Enzyme Inhibitors Market: Region-wise Outlook

On the basis of region, the market is segmented into North America, Eastern Europe, Western Europe, Asia-Pacific excluding Japan, Japan, Latin America and the Middle East and Africa. The market for enzyme inhibitors is expanding with the rising incidence of enzyme-based diseases and increasing research and development activities. In developed countries like the U.S. and Europe, the market growth for enzyme inhibitors is high because of better availability of medical facilities, diagnosis rate for the diseases, infrastructure, awareness and available treatment options. In Asia Pacific region, China, Japan, and India are most potential markets for enzyme inhibitors due to growing population, improvement in medical facilities and economic development.

Enzyme Inhibitors Market: Key Players

Some of the players in the enzyme inhibitors market are AstraZeneca, Merck and Co. Inc., Novartis AG, Pfizer Inc., Ranbaxy Laboratories Ltd, Roche-Genentech Holding Ltd., and Takeda Pharmaceuticals. Other prominent players are Abbott Laboratories Inc., Bayer AG, and Johnson and Johnson Ltd. Vendors in this market are outsourcing different parts of their research work such as toxicology testing, product characterization testing to various contract research organizations. Also, vendors are increasingly engaged in outsourcing part of their enzyme inhibitor drug manufacturing or the entire manufacturing process to various contract manufacturing organizations. Thus, the increase in outsourcing of drug manufacturing is one of the trends witnessed in the enzyme inhibitors market.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.